Metabolism, interactions and safe prescribing
How drugs are metabolised and excreted, the cytochrome P450 interactions that cause harm, genetic variation, prescribing in pregnancy, old age and organ failure, and the classification of adverse drug reactions.
By the end of this page you should be able to
- Describe phase 1 and phase 2 metabolism and give examples of active and toxic metabolites.
- Name the main CYP450 enzymes, and common inducers and inhibitors, and predict their interactions.
- Explain renal drug excretion and how pH and renal function alter it.
- Give examples of pharmacogenetic variation relevant to emergency prescribing.
- Outline prescribing in pregnancy, breastfeeding, the elderly and renal and hepatic impairment, and classify adverse drug reactions.
Why metabolise
The kidney cannot excrete lipid-soluble drugs well: they are filtered and then reabsorbed across the tubule. Metabolism makes drugs more polar so they stay in the urine or bile. Most happens in the liver (smooth endoplasmic reticulum and cytosol), with contributions from the gut wall, lungs, kidneys and plasma (esterases for suxamethonium and remifentanil).
Phase 1 reactions (oxidation, reduction, hydrolysis) add or unmask a functional group. They can inactivate a drug, activate a prodrug (codeine to morphine via CYP2D6, clopidogrel via CYP2C19, enalapril to enalaprilat) or create a toxic metabolite (paracetamol to NAPQI via CYP2E1 and 3A4; methanol to formic acid; ethylene glycol to glycolate and oxalate). Phase 2 reactions conjugate the drug or its phase 1 product with glucuronide, sulfate, glutathione, acetyl or methyl groups, usually inactivating it. Morphine-6-glucuronide is an exception: an active conjugate that accumulates in renal failure.
The cytochrome P450 system
- CYP3A4: the workhorse, metabolising about half of all drugs: midazolam, fentanyl, oxycodone, calcium channel blockers, many statins, macrolides, DOACs (partly), ciclosporin, tacrolimus.
- CYP2D6: codeine and tramadol (activation), many antidepressants and antipsychotics, metoprolol. Not inducible; highly polymorphic.
- CYP2C9: warfarin (S-enantiomer), phenytoin, NSAIDs. CYP2C19: clopidogrel activation, PPIs, diazepam. CYP1A2: theophylline, caffeine, clozapine, olanzapine; induced by smoking. CYP2E1: paracetamol to NAPQI and ethanol; induced by chronic alcohol.
- Inducers (raise enzyme amounts over days to weeks, effect lasts weeks after stopping): carbamazepine, phenytoin, phenobarbitone, rifampicin, St John's wort, chronic alcohol, smoking.
- Inhibitors (act within hours, often competitive): clarithromycin and erythromycin, azole antifungals, ritonavir, amiodarone, diltiazem and verapamil, fluoxetine and paroxetine (2D6), grapefruit juice (gut 3A4), acute alcohol, sodium valproate (glucuronidation), metronidazole and cotrimoxazole (2C9).
Interactions that matter in emergency care
- Pharmacokinetic: clarithromycin with a statin (rhabdomyolysis); a macrolide or azole with warfarin (bleeding); rifampicin or carbamazepine with the oral contraceptive pill or DOACs (failure); clarithromycin with fentanyl or oxycodone (respiratory depression); smoking cessation in hospital raising clozapine and olanzapine levels.
- Pharmacodynamic: additive sedation (opioids, benzodiazepines, alcohol, gabapentinoids); serotonin toxicity (SSRIs or MAOIs with tramadol, fentanyl, linezolid, methylene blue); QT prolongation (macrolides, ondansetron, antipsychotics, methadone); hyperkalaemia (ACE inhibitor, spironolactone, trimethoprim); the "triple whammy" of ACE inhibitor or ARB, diuretic and NSAID causing acute kidney injury; IV verapamil with a beta blocker (asystole).
- Protein binding displacement rarely matters clinically on its own, because free drug is cleared faster; it matters for narrow-index, low-extraction drugs when clearance is also reduced.
Excretion
Renal excretion = filtration + secretion minus reabsorption. Only unbound drug is filtered. Active secretion in the proximal tubule uses organic anion transporters (penicillins, methotrexate, furosemide; probenecid competes) and organic cation transporters (metformin, trimethoprim, cimetidine). Passive reabsorption of the un-ionised form depends on urine pH: alkalinising the urine traps weak acids such as salicylate in ionised form (ion trapping), which is why urinary alkalinisation enhances salicylate elimination. Biliary excretion handles large polar conjugates; enterohepatic recycling (hydrolysis by gut bacteria and reabsorption) prolongs some drugs and is interrupted by repeat-dose charcoal.
Pharmacogenetics
- Plasma cholinesterase variants: prolonged paralysis after suxamethonium (or mivacurium); reduced activity also in pregnancy and liver disease.
- CYP2D6 ultra-rapid metabolisers: too much morphine from codeine, with deaths in breastfed infants and children; poor metabolisers get no analgesia.
- Slow acetylators (N-acetyltransferase): toxicity from isoniazid (neuropathy), hydralazine and procainamide (drug-induced lupus).
- G6PD deficiency: haemolysis with oxidant drugs: primaquine, dapsone, sulfonamides, nitrofurantoin, rasburicase, methylene blue (which also fails to work).
- **HLA-B*1502 and carbamazepine (Stevens-Johnson syndrome, in people of Southeast Asian ancestry); HLA-B*5701** and abacavir hypersensitivity.
- Malignant hyperthermia susceptibility (RyR1) and acute porphyria (enzyme-inducing drugs precipitate attacks).
Special populations
- Pregnancy: higher Vd and GFR, lower albumin, slower gastric emptying. Most drugs cross the placenta. Australia uses categories (A, B1 to B3, C, D, X). Avoid warfarin (embryopathy), ACE inhibitors and ARBs (fetal renal failure in later pregnancy), valproate (neural tube defects), isotretinoin, tetracyclines (teeth), NSAIDs after about 20 weeks (oligohydramnios) and in the third trimester (ductus closure).
- Breastfeeding: most drugs pass into milk in small amounts; avoid codeine and tramadol.
- Elderly: less lean mass and water, more fat (lipophilic drugs last longer), lower GFR (creatinine underestimates it), less homeostatic reserve, polypharmacy, more sensitivity to sedatives and anticholinergics.
- Renal impairment: reduce maintenance doses of renally cleared drugs (gentamicin, vancomycin, enoxaparin, digoxin, lithium, DOACs, metformin) and avoid morphine and pethidine (active metabolites).
- Hepatic impairment: less metabolism and albumin, ascites raising Vd, encephalopathy sensitive to sedatives; no good single marker like creatinine clearance.
Adverse drug reactions
A common classification: Type A (augmented, dose-related, predictable from pharmacology: bleeding on warfarin), Type B (bizarre, not dose-related: anaphylaxis, Stevens-Johnson syndrome, idiosyncratic hepatitis), Type C (chronic: steroid osteoporosis), Type D (delayed: teratogenicity, malignancy), Type E (end of use: withdrawal, rebound tachycardia after a beta blocker), Type F (failure of therapy, often from interactions). Allergic reactions follow the four hypersensitivity types. Safe prescribing practice in Australia includes the National Inpatient Medication Chart, recording allergy and reaction type, checking high-risk medicines (the APINCHS group: anti-infectives, potassium, insulin, narcotics and sedatives, chemotherapy, heparin and anticoagulants, systems), and reporting adverse events to the TGA.
Making the answer flow
- For any interaction, say which kind (pharmacokinetic or pharmacodynamic), the mechanism, the consequence and what you would do.
- Have a short list of inducers and inhibitors you can say without hesitating.
- Use paracetamol as the worked example of a toxic metabolite: phase 2 saturation, CYP2E1, NAPQI, glutathione, acetylcysteine.
Where marks are lost
- Saying induction is quick. It takes days to weeks; inhibition takes hours.
- Saying CYP2D6 is inducible. It is not.
- Claiming protein binding displacement is usually important.
- Forgetting active metabolites when dosing in renal failure (morphine, pethidine, midazolam).
Where this meets intensive care
- Drug metabolism in critical illness changes with hepatic blood flow, enzyme function and protein binding; high-extraction drugs depend on flow, low-extraction drugs on enzyme capacity and free fraction.
- Renal replacement therapy removes small, water-soluble, poorly bound drugs with a small volume of distribution; levels of these need checking.
Viva questions
Answer each one aloud, as you would to an examiner, before you open the model points.
- 1.
Describe phase 1 and phase 2 drug metabolism with examples.
Show answer
- Purpose: increase water solubility for excretion.
- Phase 1: oxidation (CYP450, flavin monooxygenases), reduction, hydrolysis (esterases, amidases); may activate prodrugs (codeine, clopidogrel) or form toxic metabolites (NAPQI).
- Phase 2: glucuronidation (UGT: morphine, paracetamol), sulfation, glutathione conjugation (NAPQI), acetylation (isoniazid), methylation.
- Phase 2 usually inactivates; exceptions include morphine-6-glucuronide.
- 2.
A woman on warfarin is prescribed clarithromycin for pneumonia. What might happen and why?
Show answer
- Clarithromycin inhibits CYP3A4 (and contributes to raised warfarin effect); antibiotics can also alter gut flora and vitamin K production; infection itself raises INR.
- INR rises within days: bleeding risk.
- Many antibiotics raise the INR, so whichever is chosen, check the INR within a few days and adjust the warfarin dose.
- Other examples: metronidazole and cotrimoxazole inhibit CYP2C9, a stronger effect on S-warfarin.
- 3.
Name some enzyme inducers and inhibitors, and give a clinical consequence of each.
Show answer
- Inducers: carbamazepine, phenytoin, phenobarbitone, rifampicin, St John's wort, chronic alcohol, smoking.
- Consequences: contraceptive failure, subtherapeutic warfarin or DOAC, rejection with ciclosporin, paracetamol toxicity at lower ingestions (debated).
- Inhibitors: macrolides, azoles, ritonavir, amiodarone, grapefruit, valproate, SSRIs (2D6), metronidazole.
- Consequences: statin myopathy, opioid toxicity, bleeding, lamotrigine toxicity with valproate.
- Time course: inhibition hours; induction days to weeks.
- 4.
Why is codeine potentially dangerous in some patients and useless in others?
Show answer
- Prodrug: O-demethylated by CYP2D6 to morphine, which provides most of the analgesia.
- Poor metabolisers (about 7 to 10% of people of European ancestry): little analgesia.
- Ultra-rapid metabolisers (more common in some North African and Middle Eastern populations): excess morphine, respiratory depression; deaths in children after tonsillectomy and in breastfed infants.
- In Australia codeine is prescription-only, and contraindicated in children under 12 and in breastfeeding.
- 5.
How does urinary alkalinisation increase salicylate elimination?
Show answer
- Salicylic acid is a weak acid (pKa about 3); in alkaline urine more is ionised.
- Ionised drug cannot be reabsorbed passively across the tubule (ion trapping).
- Raising urine pH from about 5 to 8 increases renal clearance many-fold (logarithmic relationship).
- Requires correction of hypokalaemia (otherwise the kidney exchanges H for K and urine stays acid); monitor serum pH and potassium.
- 6.
What changes in pharmacokinetics occur in the elderly?
Show answer
- Absorption: little change overall.
- Distribution: less TBW and lean mass, more fat; water-soluble drugs (lithium, digoxin) higher levels; lipophilic drugs (diazepam) longer half-life; lower albumin.
- Metabolism: reduced hepatic mass and blood flow, reduced phase 1 more than phase 2.
- Excretion: GFR falls; creatinine underestimates decline because of lower muscle mass.
- Pharmacodynamics: more sensitive CNS, reduced baroreflex, less homeostatic reserve; polypharmacy.
- 7.
Classify adverse drug reactions with examples.
Show answer
- Type A augmented (dose-related, common, predictable): hypoglycaemia with insulin, bleeding with anticoagulants.
- Type B bizarre (idiosyncratic, immunological): anaphylaxis to penicillin, malignant hyperthermia, SJS.
- Type C chronic, D delayed, E end of use (withdrawal), F failure.
- Management: recognise, stop, treat, document, report to TGA; prevent recurrence by recording reaction type and severity.
- 8.
Which drugs should be avoided or used with caution in pregnancy?
Show answer
- Teratogens: warfarin (first trimester embryopathy), valproate, carbamazepine, phenytoin, isotretinoin, methotrexate, lithium (Ebstein anomaly, small absolute risk).
- ACE inhibitors and ARBs: fetal renal dysgenesis, oligohydramnios (second and third trimester).
- NSAIDs: oligohydramnios after about 20 weeks, premature closure of ductus arteriosus in third trimester.
- Tetracyclines: tooth discolouration; aminoglycosides: ototoxicity.
- Safer options: paracetamol, penicillins, cephalosporins, heparins, labetalol, nifedipine.
- 9.
What is G6PD deficiency and which drugs should be avoided?
Show answer
- X-linked deficiency of glucose-6-phosphate dehydrogenase, which makes NADPH in red cells to keep glutathione reduced.
- Oxidant stress causes Heinz bodies and haemolysis.
- Avoid: primaquine, dapsone, sulfonamides, nitrofurantoin, rasburicase, methylene blue (also ineffective for methaemoglobinaemia), fava beans.
- Prevalent in people from the Mediterranean, Africa, the Middle East and Asia.
Practise this week
- First Part MCQs: pharmacology
- First Part SAQs, marked part by part
- First Part cross-table vivas
- Viva Examiner: practise answering aloud
Week 3 in the other subjects
- Physiology: Lung mechanics and the work of breathing
- Measurement: Gas laws, flow and oxygen delivery
Not affiliated with the CICM. Notes are a revision aid, not a substitute for the curriculum or for clinical guidelines.